William E. Van Nostrand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William E. Van Nostrand has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Jerry P. Melchor
From the ‡Departments of Medicine and Pathology, Health Sciences Center, State University of New York, Stony Brook, NY 11794-8153 and the ¶Alzheimer Research Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129
2 shared publicationsG. William Rebeck
From the ‡Departments of Medicine and Pathology, Health Sciences Center, State University of New York, Stony Brook, NY 11794-8153 and the ¶Alzheimer Research Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129
1 shared publicationHyun Soon Cho
From the ‡Departments of Medicine and Pathology, Health Sciences Center, State University of New York, Stony Brook, NY 11794-8153 and the ¶Alzheimer Research Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129
1 shared publicationJ P Melchor
1 shared publicationJerry Melchor
Departments of Medicine and Pathology, State University of New York, Stony Brook, New York 11794–8153, USA
1 shared publicationJudianne Davis
Departments of Medicine and Pathology, State University of New York, Stony Brook, New York 11794–8153, USA
1 shared publication
Latest Publications
- Open Access
- 1 August 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (35) , 32860-32866
Pathogenic Effects of D23N Iowa Mutant Amyloid β-Protein
- 1 August 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (35) , 32860-32866
Open AccessPathogenic Effects of D23N Iowa Mutant Amyloid β-Protein
- 1 July 2001
- p. 20-7
Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells.
Cerebral amyloid beta-protein (Abeta) angiopathy (CAA) is a common pathological feature of Alzheimer's disease and several related disorders. In this condition, the accumulation offibrillar Abeta deposits is associated with degeneration of smooth muscle cells within the cerebral blood vessel wall. We have been using primary cultures of human cerebrovascular smooth muscle (HCSM) cells to investigate pathogenic mechanisms of Abeta in CAA. The specific assembly of Abeta fibrils on the surface of these cell types initiates several pathologic responses including increased expression and cell surface accumulation of the Abeta precursor protein (AbetaPP) and induction of apoptotic cell death. These pathologic responses are not observed with preparations of Abeta that are assembled into fibrils in solution, further underscoring the significance of the fibril assembly process on the cell surface. Since cell surface Abeta fibril assembly is the key initiator of the cerebrovascular cellular pathology that is observed in vitro, inhibition of this process remains an attractive therapeutic target for CAA. We have tested the efficacy of a variety of compounds that have been reported to inhibit Abeta fibril assembly in solution and block the neurotoxic properties of Abeta in vitro. The vast majority of these agents were ineffective in inhibiting the cell surface fibrillar assembly of Abeta and the subsequent pathologic responses in the cultured HCSM cells. This emphasizes the likely requirement of therapeutic compounds that are effective in disrupting cell surface-driven Abeta fibril assembly in the treatment of CAA.
- 1 July 2001
- p. 20-7
Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells.
Cerebral amyloid beta-protein (Abeta) angiopathy (CAA) is a common pathological feature of Alzheimer's disease and several related disorders. In this condition, the accumulation offibrillar Abeta deposits is associated with degeneration of smooth muscle cells within the cerebral blood vessel wall. We have been using primary cultures of human cerebrovascular smooth muscle (HCSM) cells to investigate pathogenic mechanisms of Abeta in CAA. The specific assembly of Abeta fibrils on the surface of these cell types initiates several pathologic responses including increased expression and cell surface accumulation of the Abeta precursor protein (AbetaPP) and induction of apoptotic cell death. These pathologic responses are not observed with preparations of Abeta that are assembled into fibrils in solution, further underscoring the significance of the fibril assembly process on the cell surface. Since cell surface Abeta fibril assembly is the key initiator of the cerebrovascular cellular pathology that is observed in vitro, inhibition of this process remains an attractive therapeutic target for CAA. We have tested the efficacy of a variety of compounds that have been reported to inhibit Abeta fibril assembly in solution and block the neurotoxic properties of Abeta in vitro. The vast majority of these agents were ineffective in inhibiting the cell surface fibrillar assembly of Abeta and the subsequent pathologic responses in the cultured HCSM cells. This emphasizes the likely requirement of therapeutic compounds that are effective in disrupting cell surface-driven Abeta fibril assembly in the treatment of CAA.
- 1 September 2000
- Published by Elsevier in Molecular Medicine Today
- Vol. 6 (9) , 373-374
Cellular and transgenic animal models of cerebrovascular amyloidosis.
- 1 September 2000
- Published by Elsevier in Molecular Medicine Today
- Vol. 6 (9) , 373-374
Cellular and transgenic animal models of cerebrovascular amyloidosis.
- 1 May 2000
- Published by Wiley in Journal of Neurochemistry
- Vol. 74 (5) , 2209-2212
Charge Alterations of E22 Enhance the Pathogenic Properties of the Amyloid β‐Protein
Cerebral amyloid angiopathy (CAA) due to amyloid β‐protein (Aβ) is a key pathological feature of patients with Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis, Dutch‐type (HCHWA‐D). The CAA in these disorders is characterized by deposition of Aβ in the smooth muscle cells within the cerebral vessel wall. Recently, a new mutation in Aβ, E22K, was identified in several Italian families that, like HCHWA‐D, is associated with CAA and hemorrhagic stroke. These two similar disorders, stemming from amino acid substitutions at position 22 of Aβ, implicate the importance of this site in the pathology of HCHWA. Previously we showed that HCHWA‐D Aβ1‐40 containing the E22Q substitution induces robust pathologic responses in cultured human cerebrovascular smooth muscle cells (HCSM cells), including highly elevated levels of cell‐associated Aβ precursor (AβPP) and cell death. In the present study, a series of E22 mutant Aβ1‐40 peptides were synthesized, and their pathogenic properties toward cultured HCSM cells were evaluated. Quantitative fluorescence analyses showed that mutant Aβ1‐40 peptides either containing a loss of charge (E22Q and E22A) or a change of charge (E22K) bind to the surface of HCSM cells and form amyloid fibrils. Similarly, this same group of E22 mutant Aβ1‐40 peptides caused enhanced pathologic responses in HCSM cells. In contrast, wild‐type E22 or the charge‐preserving E22D Aβ1‐40 peptides were devoid of any of these pathogenic properties. These data suggest that a change or loss of charge at position 22 of Aβ enhances the pathogenic effects of the peptide toward HCSM cells and may contribute to the pathogenesis of the phenotypically related HCHWA disorders.
- 1 May 2000
- Published by Wiley in Journal of Neurochemistry
- Vol. 74 (5) , 2209-2212
Charge Alterations of E22 Enhance the Pathogenic Properties of the Amyloid β‐Protein
Cerebral amyloid angiopathy (CAA) due to amyloid β‐protein (Aβ) is a key pathological feature of patients with Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis, Dutch‐type (HCHWA‐D). The CAA in these disorders is characterized by deposition of Aβ in the smooth muscle cells within the cerebral vessel wall. Recently, a new mutation in Aβ, E22K, was identified in several Italian families that, like HCHWA‐D, is associated with CAA and hemorrhagic stroke. These two similar disorders, stemming from amino acid substitutions at position 22 of Aβ, implicate the importance of this site in the pathology of HCHWA. Previously we showed that HCHWA‐D Aβ1‐40 containing the E22Q substitution induces robust pathologic responses in cultured human cerebrovascular smooth muscle cells (HCSM cells), including highly elevated levels of cell‐associated Aβ precursor (AβPP) and cell death. In the present study, a series of E22 mutant Aβ1‐40 peptides were synthesized, and their pathogenic properties toward cultured HCSM cells were evaluated. Quantitative fluorescence analyses showed that mutant Aβ1‐40 peptides either containing a loss of charge (E22Q and E22A) or a change of charge (E22K) bind to the surface of HCSM cells and form amyloid fibrils. Similarly, this same group of E22 mutant Aβ1‐40 peptides caused enhanced pathologic responses in HCSM cells. In contrast, wild‐type E22 or the charge‐preserving E22D Aβ1‐40 peptides were devoid of any of these pathogenic properties. These data suggest that a change or loss of charge at position 22 of Aβ enhances the pathogenic effects of the peptide toward HCSM cells and may contribute to the pathogenesis of the phenotypically related HCHWA disorders.
- 1 April 2000
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 903 (1) , 89-96
Cerebrovascular Smooth Muscle Cell Surface Fibrillar Aβ: Alteration of the Proteolytic Environment in the Cerebral Vessel Wall
Cerebrovascular deposition of the amyloid beta-protein (A beta) is a common pathologic event in patients with Alzheimer's disease (AD) and certain related disorders including hereditary cerebral hemorrhage with amyloidosis Dutch-type (HCHWA-D). A beta deposition occurs primarily in the medial layer of the cerebral vessel wall in an assembled fibrillar state. These deposits are associated with several pathological responses including degeneration of the smooth muscle cells in the cerebral vessel wall. Severe cases of cerebrovascular A beta deposition are also accompanied by loss of vessel wall integrity and hemorrhagic stroke. Although the reasons for this pathological consequence are unclear, altered proteolytic mechanisms within the cerebral vessel wall may be involved. Recent studies from our laboratory have shown that cell-surface assembly of A beta into fibrillar structures causes cellular degeneration via an apoptotic pathway and creates an altered proteolytic microenvironment on the cell surface of human cerebrovascular smooth muscle cells (HCSM cells). For example, HCSM cell-surface A beta fibrils serve as a site for tight binding of cell-secreted amyloid beta-precursor protein (A beta PP). Since A beta PP is a potent inhibitor of key proteinases of coagulation cascade, its enhanced localization on the A beta fibrils would provide an strong anticoagulant environment. In addition, HCSM cell-surface A beta fibrils are potent stimulators of tissue plasminogen activator (tPA) creating a profibrinolytic milieu. Our findings indicate that A beta fibril assembly on the HCSM cell surface causes cellular degeneration and results in both a strong anticoagulant and fibrinolytic environment. Together, these altered proteolytic events could create a setting that is conducive to loss of vessel wall integrity and hemorrhagic stroke.
- 1 April 2000
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 903 (1) , 89-96
Cerebrovascular Smooth Muscle Cell Surface Fibrillar Aβ: Alteration of the Proteolytic Environment in the Cerebral Vessel Wall
Cerebrovascular deposition of the amyloid beta-protein (A beta) is a common pathologic event in patients with Alzheimer's disease (AD) and certain related disorders including hereditary cerebral hemorrhage with amyloidosis Dutch-type (HCHWA-D). A beta deposition occurs primarily in the medial layer of the cerebral vessel wall in an assembled fibrillar state. These deposits are associated with several pathological responses including degeneration of the smooth muscle cells in the cerebral vessel wall. Severe cases of cerebrovascular A beta deposition are also accompanied by loss of vessel wall integrity and hemorrhagic stroke. Although the reasons for this pathological consequence are unclear, altered proteolytic mechanisms within the cerebral vessel wall may be involved. Recent studies from our laboratory have shown that cell-surface assembly of A beta into fibrillar structures causes cellular degeneration via an apoptotic pathway and creates an altered proteolytic microenvironment on the cell surface of human cerebrovascular smooth muscle cells (HCSM cells). For example, HCSM cell-surface A beta fibrils serve as a site for tight binding of cell-secreted amyloid beta-precursor protein (A beta PP). Since A beta PP is a potent inhibitor of key proteinases of coagulation cascade, its enhanced localization on the A beta fibrils would provide an strong anticoagulant environment. In addition, HCSM cell-surface A beta fibrils are potent stimulators of tissue plasminogen activator (tPA) creating a profibrinolytic milieu. Our findings indicate that A beta fibril assembly on the HCSM cell surface causes cellular degeneration and results in both a strong anticoagulant and fibrinolytic environment. Together, these altered proteolytic events could create a setting that is conducive to loss of vessel wall integrity and hemorrhagic stroke.
- 1 August 1999
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 38 (35) , 11570-11576
Plasmin Cleavage of the Amyloid β-Protein: Alteration of Secondary Structure and Stimulation of Tissue Plasminogen Activator Activity
Cerebrovascular amyloid β-protein (Aβ) deposition, a key pathological feature of Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis Dutch-type, can lead to intracerebral hemorrhage; however, the mechanism for this remains unclear. Assembled Aβ is a potent stimulator of tissue-type plasminogen activator (tPA) in vitro. Herein, we investigated the stimulation of tPA by freshly solubilized Aβ1-40. The rate of tPA stimulation by Aβ1-40 increased dramatically over time, suggesting that Aβ may be altered during the course of the reaction. SDS-PAGE analysis showed that Aβ1-40 was cleaved during the course of the reaction. Subsequent studies showed that it was plasmin, the product of tPA activation of plasminogen, that specifically cleaved Aβ1-40 in the amino terminal region between Arg5 and His6. Plasmin effectively cleaved a chromogenic substrate corresponding to this cleavage site in Aβ. Circular dichroism spectral analysis showed that Aβ6-40 adopted a strong β-sheet secondary structure. This truncated Aβ6-40 peptide was a potent stimulator of tPA in vitro. Our results indicate that β-sheet secondary structure of Aβ, which can be promoted by plasmin cleavage, stimulates tPA activity. These findings suggest that pathologic interactions between Aβ, tPA, and plasmin in the cerebral vessel wall could result in excessive proteolysis contributing to intracerebral hemorrhages.
- 1 August 1999
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 38 (35) , 11570-11576
Plasmin Cleavage of the Amyloid β-Protein: Alteration of Secondary Structure and Stimulation of Tissue Plasminogen Activator Activity
Cerebrovascular amyloid β-protein (Aβ) deposition, a key pathological feature of Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis Dutch-type, can lead to intracerebral hemorrhage; however, the mechanism for this remains unclear. Assembled Aβ is a potent stimulator of tissue-type plasminogen activator (tPA) in vitro. Herein, we investigated the stimulation of tPA by freshly solubilized Aβ1-40. The rate of tPA stimulation by Aβ1-40 increased dramatically over time, suggesting that Aβ may be altered during the course of the reaction. SDS-PAGE analysis showed that Aβ1-40 was cleaved during the course of the reaction. Subsequent studies showed that it was plasmin, the product of tPA activation of plasminogen, that specifically cleaved Aβ1-40 in the amino terminal region between Arg5 and His6. Plasmin effectively cleaved a chromogenic substrate corresponding to this cleavage site in Aβ. Circular dichroism spectral analysis showed that Aβ6-40 adopted a strong β-sheet secondary structure. This truncated Aβ6-40 peptide was a potent stimulator of tPA in vitro. Our results indicate that β-sheet secondary structure of Aβ, which can be promoted by plasmin cleavage, stimulates tPA activity. These findings suggest that pathologic interactions between Aβ, tPA, and plasmin in the cerebral vessel wall could result in excessive proteolysis contributing to intracerebral hemorrhages.